Search
Aclarion Inc
ACONAdd to Watchlist
3.090USD
+0.070+2.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
7.55MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.32%
5 Days
+8.42%
1 Month
-12.46%
6 Months
-37.95%
Year to Date
-32.83%
1 Year
-58.52%
Key Figures
3.045Open
3.110High
21.27KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.87%Turnover Ratio
3.020Prev. Close
3.020Low
48.12KTurnover
LossP/E Static
0.38P/B
0.00%Div Yield TTM
-43.37%ROA
12.03052wk High
1.14Volume Ratio
-7.05MNet Profit
2.44MShares
-5.6302EPS TTM
1.20Beta
-45.43%ROE
2.34052wk Low
2.98%Amplitude
17.74%Gross Margin
7.55MMarket Cap
-3.34Reward/Risk
4.32%Risk Rate
TradingKey Stock Score of Aclarion Inc
Currency: USD Updated: 2026-07-02Key Insights
Aclarion Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 207 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aclarion Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Aclarion Inc Highlights
StrengthsRisks
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Growing
The company is in a growing phase, with the latest annual income totaling USD 75.73K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 75.73K.
Undervalued
The company’s latest PE is -0.55, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 58.05K shares, increasing 22.32% quarter-over-quarter.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
7.500
Target Price
+148.34%
Upside Space
Aclarion Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aclarion Inc Info
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Ticker SymbolACON
CompanyAclarion Inc
CEONess (Brent)
Websitehttps://aclarion.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Aclarion Inc (ACON)?
The current price of Aclarion Inc (ACON) is 3.09.
What is the symbol of Aclarion Inc?
The ticker symbol of Aclarion Inc is ACON.
What is the 52-week high of Aclarion Inc?
The 52-week high of Aclarion Inc is 12.03.
What is the 52-week low of Aclarion Inc?
The 52-week low of Aclarion Inc is 2.34.
What is the market capitalization of Aclarion Inc?
The market capitalization of Aclarion Inc is 7.55M.
Is Aclarion Inc (ACON) currently rated as Buy, Hold, or Sell?
According to analysts, Aclarion Inc (ACON) has an overall rating of Buy, with a price target of 7.50.
What is the Earnings Per Share (EPS TTM) of Aclarion Inc (ACON)?
The Earnings Per Share (EPS TTM) of Aclarion Inc (ACON) is -13.61.